The Latest Breaking News from NovoCure

Novocure sees its Relative Strength Rating hit the elite 90-plus level.

Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer.

Novocure said Monday its cancer treatment failed to make a difference for ovarian cancer patients, and NVCR stock crashed.

The stock market rally showed strong gains in small caps, while the Nasdaq held up. Apple unveiled its Vision Pro goggles, while the SEC targeting crypto giants.

Novocure shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

A medical device from Novocure extended overall survival for lung cancer patients, but the company's shares crashed on muddy test results.

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.26%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.21%. U.S. stock index futures this morning are moderately lower as the markets await any new developments on the debt ceiling stalemate. President Biden will meet...

Novocure will win a 10% of its targeted lung cancer market, an analyst predicted Tuesday as he examined NVCR stock's double-digit drop.

Adding Novocure's medical device to standard drugs improved survival for late-stage lung cancer patients, leading NVCR stock to soar Thursday.